Cutting-Edge Microlobectomy Research Using Dextera’s MicroCutter Device Presented at the 2016 EACTS Annual Conference
October 04 2016 - 8:00AM
Dextera Surgical Inc. (Nasdaq:DXTR), manufacturer of the
smallest-profile and most maneuverable articulating surgical
stapling platform on the market for minimally invasive surgery,
today announced the presentation of research featuring the
company’s surgical stapling technology for video assisted thoracic
surgery (VATS) in lung surgery. Joel Dunning, M.D., of the
Department of Thoracic Surgery at James Cook University Hospital in
Middlesbrough, UK, presented the results of the study at the
European Association of Cardio-Thoracic Surgery (EACTS).
The study, titled Microlobectomy, a Novel Form of
VATS Lobectomy, focused on the early experience of the
microlobectomy technique. Data included 72 patients who received
microlobectomy from leading thoracic surgeons at six hospitals
around the world including Shanda Blackmon (Mayo Clinic), Bill
Walker (Royal Infirmary Edinburgh), Rene Petersen and Henrik Hansen
(Rigshospitalet Copenhagen), and others, to investigate the
potential of this novel technique to reduce the pain and
invasiveness experienced by patients.
Microlobectomy is similar to current VATS
techniques, but uses only 5mm incisions between the ribs instead of
12mm incisions, and a small incision below the ribs. A majority of
the procedures in the study were enabled by the MicroCutter 5/80,
which is roughly the width of a pencil and offers up to 80 degrees
of articulation – making it easier for surgeons to perform this
innovative technique.
The early results of this ongoing international
evaluation of microlobectomy have demonstrated significant benefits
for patients, with 22 percent going home after one day, and more
than 40 percent going home on day two, and a short learning curve
for surgeons.
“Microlobectomy offers important benefits for
patients. Because the smaller incisions cause less trauma,
especially to the sensitive nerves in the ribcage, patients
experience less pain – which can lead to accelerated recovery times
and shorter hospital stays,” said Dr. Dunning. “As a key
breakthrough that facilitates this procedure, the MicroCutter
represents a significant innovation for thoracic surgery.”
“We are excited that the MicroCutter is making new
procedural approaches to video assisted thoracic surgery (VATS)
possible, translating into measurable benefits for patients, as
demonstrated in the study’s findings,” said Julian Nikolchev,
president and CEO of Dextera.
MicroCutter Indication Information
The MicroCutter 5/80 Stapler is manufactured and cleared for use in
the United States for transection and resection in multiple open or
minimally invasive urologic, thoracic and pediatric surgical
procedures, as well as application for transection, resection
and/or creation of anastomoses in the small and large intestine,
and the transection of the appendix. The MicroCutter 30 White
Reload has application in vascular tissue.
About Dextera SurgicalDextera
Surgical (Nasdaq:DXTR) designs and manufactures proprietary
stapling devices for minimally invasive surgical procedures. In the
U.S., surgical staplers are routinely used in more than one million
minimally invasive laparoscopic, video-assisted or robotic-assisted
surgical procedures annually.
The company's signature proprietary technology, the
MicroCutter 5/80 Stapler, is the world's first and only
five-millimeter surgical stapler that articulates to 80 degrees in
each direction. As the smallest-profile articulating stapler
available today, the MicroCutter 5/80 Stapler may reduce the amount
of dissection and tissue handling required to position the stapler
in confined spaces, enabling access to difficult-to-reach
anatomy. The cartridge-based device's small size and wide
articulation range are designed to enhance the surgeon's access and
visualization at the surgical site and to mitigate limitations on
the advancement of minimally invasive surgical approaches created
by larger stapling devices.
Dextera Surgical also markets the only automated
anastomosis devices for coronary artery bypass graft (CABG) surgery
on the market today: the C-Port® Distal Anastomosis Systems and
PAS-Port® Proximal Anastomosis System. These products, sold by
Dextera Surgical under the Cardica brand name, have demonstrated
long-term reliable clinical performance for more than a decade.
Forward-Looking Statements The
statements in this press release regarding Dextera Surgical’s
beliefs as to the expected benefits to be achieved from the use of
its MicroCutter 5/80 are "forward-looking statements." There are a
number of important factors that could cause Dextera Surgical’s
results to differ materially from those indicated by these
forward-looking statements, including: that Dextera Surgical may
not be successful in its efforts to make the improvements necessary
to its enhanced MicroCutter device due to unanticipated technical
or other difficulties; risks inherent in obtaining regulatory
approvals; as well as other risks detailed from time to time in
Dextera Surgical’s reports filed with the U.S. Securities and
Exchange Commission, including its Quarterly Report on Form 10-Q
for the quarter ended March 31, 2016, under the caption “Risk
Factors.” Dextera Surgical expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein. You are encouraged to
read Dextera Surgical’s reports filed with the U.S. Securities and
Exchange Commission, available at www.sec.gov.
Contact:
Investors:
Bob Newell
Vice President, Finance and Chief Financial Officer
(650) 331-7133
investors@dexterasurgical.com
Media Contact:
Nicole Osmer
Tel. 650.454.0504
nicole@nicoleosmer.com